Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Exelixis (EXEL) Q3 Earnings & Sales Top, Cabometyx Aids Growth
12:48pm, Wednesday, 02'nd Nov 2022
Exelixis (EXEL) tops earnings and sales estimates for the third quarter as demand for its lead drug, Cabometyx, remains strong.
Exelixis (EXEL) Q3 2022 Earnings Call Transcript
05:30am, Wednesday, 02'nd Nov 2022 The Motley Fool
EXEL earnings call for the period ending September 30, 2022.
Exelixis, Inc. (EXEL) Q3 2022 Earnings Call Transcript
08:50pm, Tuesday, 01'st Nov 2022
Exelixis, Inc. (NASDAQ:EXEL ) Q3 2022 Earnings Conference Call November 1, 2022 5:00 PM ET Company Participants Susan Hubbard – Executive Vice President of Public Affairs and Investor Relations Mike
Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates
06:49pm, Tuesday, 01'st Nov 2022
Exelixis (EXEL) delivered earnings and revenue surprises of 24% and 1.88%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
02:27pm, Tuesday, 01'st Nov 2022 Benzinga
Upgrades
For AnaptysBio Inc (NASDAQ:ANAB), Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio earned $1.15 in the second quarter, compared to $0.02 in the year-ago quarter. The sto
Drug/Biotech Stocks' Q3 Earnings on Nov 1: PFE, LLY & More
08:07pm, Monday, 31'st Oct 2022 Zacks Investment Research
Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Nov 1.
Nasdaq Bear Market: 5 Magnificent Growth Stocks You'll Regret Not Buying on the Dip
09:06am, Saturday, 29'th Oct 2022 The Motley Fool
With the Nasdaq Composite down as much as 38% from its peak, these highly innovative companies are ripe for the picking.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
01:40pm, Friday, 28'th Oct 2022 Zacks Investment Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
2 Top Biotech Stocks to Buy for the Long Haul
12:15pm, Friday, 28'th Oct 2022 The Motley Fool
Both drugmakers have outperformed the market in the past year.
EXEL or TECH: Which Is the Better Value Stock Right Now?
03:40pm, Thursday, 27'th Oct 2022 Zacks Investment Research
EXEL vs. TECH: Which Stock Is the Better Value Option?
Are Investors Undervaluing Exelixis (EXEL) Right Now?
01:40pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
EXEL or TECH: Which Is the Better Value Stock Right Now?
12:47pm, Thursday, 27'th Oct 2022
EXEL vs. TECH: Which Stock Is the Better Value Option?
Are Investors Undervaluing Exelixis (EXEL) Right Now?
11:20am, Thursday, 27'th Oct 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Analysts Estimate Horizon Therapeutics (HZNP) to Report a Decline in Earnings: What to Look Out for
02:02pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
02:01pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
